Clean air for Pharmaxis
Wednesday, 13 August, 2008
Results from the Phase II clinical trial of Pharmaxis' [ASX: PXS] Bronchitol treatment in cystic fibrosis patients have produced promising results.
The study showed that Bronchitol was able to improve lung function in cystic fibrosis sufferers, as measured by forced vital capacity and FEV1 - the amount of air that can be forcibly exhaled in one second.
Improvements in lung function were dose-dependant, with the best results occurring in the patients which had received the highest dose. Pharmaxis has concluded that 400mg is the optimal Bronchitol dose.
Bronchitol is designed to hydrate the airway surface, improve lung hygiene and promote normal lung clearance. It is a proprietary formulation of mannitol, administered as a dry powder through a hand-held inhaler.
Diabetes changes the structure of our hearts, study finds
Type 2 diabetes directly alters the heart's structure and energy systems, which explains why...
Beta blockers could halt triple negative breast cancer
Researchers have identified a molecular biomarker in triple negative breast cancer tumours which...
Common arthritis drug also lowers blood pressure
Scientists have known for a while that methotrexate helps with inflammation, but it may also help...
